Resumo

GONZALEZ ALVAREZ, A.; GOMEZ BARRERA, M.; BORRAS BLASCO, J.  e  GINER SERRER, E. J.. Adalimumab versus etanercept in the treatment of active rheumatoid arthritis: cost-effectiveness analysis. Farm Hosp. [online]. 2013, vol.37, n.4, pp.286-294. ISSN 2171-8695.  https://dx.doi.org/10.7399/FH.2013.37.4.593.

Purpose: To assess the effectiveness and efficiency of the two alternatives mainly used in our area, etanercept (ETN) and adalimumab (ADA), for the treatment of rheumatoid arthritis (RA) patients under real clinical practice. Material and methods: We performed a retrospective observational study, where the time horizon was 12 months referred to the year 2012. We analyzed the characteristics of patients, and the effectiveness and efficiency of ETN and ADA in our study population. Inclusion criteria: patients over 18 years, diagnosed with RA treated at the outpatient clinic of the Rheumatology Health Sector of Teruel. We determined the mean decrease in DAS28 value (DAS28r) of each drug and we defined as a unit of effectiveness in pharmacoeconomic study, a DAS28 value at baseline (DAS28a) less than 3.2 points and DAS28r greater than 1.2 points. As parameter to determine the cost-effectiveness of both alternatives we used net health benefits (NHB). Results: The average value of DAS28a was 2,25 and 2,72 points for ETN and ADA respectively, with a value of DAS28r 1,01 points higher for ETN, although not statistically significant (p> 0.05). NHB obtained a value of -0.121, 95% CI (-0.951 to 0.709). Conclusions: Both alternatives are effective in the treatment of RA, although it seems to be a trend in favor of ETN in cost-effectiveness degree.

Palavras-chave : Rheumatoid arthritis; Cost-effectiveness analysis; Adalimumab; Etanercept; Tumor necrosis factor alpha antagonists; Disease Activity Score 28.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )